2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Marshall Wace LLP

Marshall Wace LLP reduced its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 41.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 275,536 shares of the company's stock after selling 193,347 shares during the period. Marshall Wace LLP owned 0.53% of 2seventy bio worth $810,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of 2seventy bio in the fourth quarter worth $32,000. Raymond James Financial Inc. acquired a new position in 2seventy bio in the 4th quarter valued at about $52,000. Intech Investment Management LLC grew its holdings in shares of 2seventy bio by 41.1% during the fourth quarter. Intech Investment Management LLC now owns 20,688 shares of the company's stock worth $61,000 after buying an additional 6,030 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of 2seventy bio by 23.2% in the fourth quarter. Wells Fargo & Company MN now owns 32,532 shares of the company's stock valued at $96,000 after buying an additional 6,133 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of 2seventy bio by 9.5% during the fourth quarter. Rhumbline Advisers now owns 84,670 shares of the company's stock valued at $249,000 after buying an additional 7,379 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on TSVT shares. Leerink Partners reissued a "market perform" rating and set a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 2seventy bio in a research note on Thursday, April 24th. Leerink Partnrs cut shares of 2seventy bio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley dropped their price target on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $5.60.

2seventy bio Stock Down 0.1 %

Shares of TSVT stock traded down $0.01 during mid-day trading on Tuesday, reaching $5.00. The company's stock had a trading volume of 231,714 shares, compared to its average volume of 615,889. The firm has a market capitalization of $265.87 million, a PE ratio of -2.69 and a beta of 1.04. The company's 50 day simple moving average is $4.59 and its 200-day simple moving average is $3.75. 2seventy bio, Inc. has a 12-month low of $2.29 and a 12-month high of $5.30.

2seventy bio (NASDAQ:TSVT - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.08). 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $12.84 million. As a group, research analysts anticipate that 2seventy bio, Inc. will post -1.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO William D. Baird III sold 5,092 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $25,205.40. Following the completion of the sale, the chief executive officer now directly owns 1,121,034 shares in the company, valued at $5,549,118.30. This trade represents a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $4.93, for a total value of $25,350,607.23. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,152,093 shares of company stock valued at $25,400,018. Corporate insiders own 7.20% of the company's stock.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.